#gsk

[ follow ]
#share-price #corporate-restructuring #pharmaceutical-competition #co-ceo-model #ceo-leadership #emma-walmsley
Business
fromwww.theguardian.com
13 hours ago

GSK, take two: the bullish tone at the top is finally more convincing | Nils Pratley

GSK's share price returned to its post-merger level after 25 years, indicating cautious investor optimism amid restructuring and leadership-driven changes.
Business
fromFortune
3 months ago

GSK chief doesn't buy that the CEO role has become unsustainable | Fortune

GSK CEO Emma Walmsley rejects the co-CEO model, urging CEOs to fully commit to a single leadership role despite its demands.
fromwww.theguardian.com
4 months ago

Pharma shake-up: Surprise change of CEO at GSK, as AstraZeneca announces New York stock market listing business live

GSK tells investors: Luke is a highly respected, experienced global biopharma leader, having worked at senior levels in the US, Europe and Asia, at AstraZeneca, Roche and Sanofi-Aventis, prior to joining GSK. This experience, and significant contribution to GSK, mean he is exceptionally well-qualified to lead the company, and to deliver the patient and shareholder value inherent in the company's future ambitions.
Business
[ Load more ]